Xuejun Xiao | Bioinformatics | Best Researcher Award

Published on by Technology Scientists

Best Researcher Award

                    Xuejun Xiao
Affiliation Xinjiang Medical University
Country China
Scopus ID 56640335200
Documents 8
Citations 132
h-index 4
Subject Area Bioinformatics
Event Technology Scientists Awards

Xuejun Xiao, Xinjiang Medical University

Xuejun Xiao is affiliated with Xinjiang Medical University, China, and has contributed to bioinformatics and biomedical research through scholarly publications indexed in Scopus. The researcher has authored eight indexed publications, received more than one hundred citations, and demonstrated continued academic engagement in cancer biology, immunology, and nanomedicine research. [1]

Abstract

Xuejun Xiao has contributed to interdisciplinary bioinformatics research with emphasis on cancer biology, immune regulation, molecular therapeutics, and nanoparticle-assisted drug delivery. Published studies investigate immune checkpoint modulation, mechanisms of chemotherapy resistance, and advanced biomedical technologies supporting precision medicine. The available scholarly record demonstrates sustained scientific productivity and measurable citation impact within indexed literature. These achievements indicate meaningful participation in translational biomedical research while supporting future innovation in computational biology, oncology, and therapeutic development through collaborative scientific investigation and evidence-based methodologies. [1] [2] [3]

Keywords

Bioinformatics, Cancer Research, Nanoparticles, Drug Delivery, Gastric Cancer, LUAD, Immunotherapy, Siglec-15, Precision Medicine, Computational Biology.

Introduction

Bioinformatics integrates computational methods with biomedical sciences to improve disease understanding and therapeutic discovery. Xuejun Xiao’s scholarly activities align with this interdisciplinary approach by examining molecular mechanisms associated with cancer progression, immune regulation, and targeted treatment strategies through evidence-based experimental investigations. [1]

Research Profile

The research profile demonstrates experience in oncology, molecular biology, and translational medicine. Indexed publications, citation performance, and collaborative scientific outputs illustrate continued participation in biomedical research focused on identifying clinically relevant biomarkers and innovative therapeutic approaches supporting improved patient outcomes. [2]

Research Contributions

Research contributions include investigations into nanoparticle-mediated antibody delivery, immune checkpoint inhibition, macrophage polarization, and mechanisms responsible for chemotherapy resistance. These studies provide valuable scientific knowledge supporting precision oncology and future therapeutic development through multidisciplinary biomedical research collaborations. [1] [3]

Publications

The Scopus record reports eight indexed publications covering bioinformatics, immunology, cancer biology, and targeted therapeutics. These publications have received academic recognition through citations, reflecting their relevance within contemporary biomedical research and contribution to ongoing scientific discussions in related disciplines. [1]

Research Impact

Citation metrics indicate measurable academic influence, with published research supporting continued investigations into molecular oncology and immunotherapy. The combination of citation performance, interdisciplinary collaborations, and translational relevance highlights the significance of the research within biomedical and bioinformatics communities. [2]

Award Suitability

Based on available scholarly indicators, publication quality, citation record, and sustained contributions to bioinformatics and biomedical sciences, Xuejun Xiao demonstrates qualifications consistent with recognition under the Best Researcher Award for advancing scientific knowledge through impactful and collaborative academic research. [1]

Conclusion

Xuejun Xiao’s academic portfolio reflects meaningful contributions to bioinformatics and cancer research through peer-reviewed publications addressing clinically important biomedical challenges. Continued research activity and scholarly collaboration are expected to further support innovation, translational medicine, and evidence-based healthcare advancement. [1]

External Links

References

  1. Xiao, X., et al. (2026). Application of nanoparticles in antibody drug delivery. Frontiers in Bioengineering and Biotechnology.
    https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1759915/full
  2. Xiao, X., et al. (2022). A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating macrophage polarization in the tumor microenvironment. Cancer Letters.
    https://www.sciencedirect.com/science/article/abs/pii/S1043661822002146
  3. Xiao, X., et al. (2020). PLOD2 increases resistance of gastric cancer cells to 5-fluorouracil by upregulating BCRP and inhibiting apoptosis. Cell Biology International.
    https://pubmed.ncbi.nlm.nih.gov/32284742/
  4. Elsevier. (n.d.). Scopus author details: Xuejun Xiao, Author ID 56640335200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56640335200

Vasuk Gautam | Bioinformatics | Best Researcher Award

Published on by Technology Scientists

Dr. Vasuk Gautam | Bioinformatics | Best Researcher Award

Sr.Scientist | Norton Research Institute | United States

Dr. Vasuk Gautam is an emerging researcher whose work spans metabolomics, biomarker discovery, and computational methods for enhancing analytical confidence in high-throughput biological studies. With a record of 24 peer-reviewed publications, 13 h-index and over 3,102 citations, Gautam has established a strong early-career footprint marked by methodological innovation and extensive interdisciplinary collaboration. His contributions focus particularly on developing frameworks for improving metabolite identification accuracy—an essential challenge in metabolomics that directly influences the reliability of biomedical and environmental research. Notably, his recent work introducing the concept of “Identification Probability” provides a transferable, automated metric for evaluating identification confidence, positioning it as a potentially transformative tool for large-scale metabolomic pipelines. In parallel, Gautam has contributed significantly to the development of MarkerDB 2.0, a comprehensive biomarker database that integrates molecular, clinical, and contextual information to support precision medicine, translational research, and global health initiatives. His scholarship reflects a blend of computational rigor, domain expertise, and a commitment to open-access scientific resources. Gautam’s collaborations include partnerships with over 180 co-authors, underscoring his active engagement with diverse research groups and his ability to contribute meaningfully to multi-institutional projects. This collaborative network spans biochemistry, bioinformatics, systems biology, and clinical sciences, highlighting the broad applicability and relevance of his expertise. Through both his methodological contributions and his involvement in global data-resource efforts, Gautam’s work supports reproducibility, accessibility, and evidence-based discovery in molecular life sciences. His growing citation impact and participation in influential open-access initiatives demonstrate both scientific merit and societal relevance, particularly in areas related to disease diagnostics, personalized healthcare, and data-driven research infrastructures.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

1. Wishart, D. S., Guo, A. C., Oler, E., Wang, F., Anjum, A., Peters, H., Dizon, R., … (2022). HMDB 5.0: The human metabolome database for 2022. Nucleic Acids Research, 50(D1), D622–D631.

Cited by: 2116

2. Knox, C., Wilson, M., Klinger, C. M., Franklin, M., Oler, E., Wilson, A., Pon, A., Cox, J., … (2024). DrugBank 6.0: The DrugBank knowledgebase for 2024. Nucleic Acids Research, 52(D1), D1265–D1275.

Cited by: 1112

3. Wishart, D. S., Han, S., Saha, S., Oler, E., Peters, H., Grant, J. R., Stothard, P., … (2023). PHASTEST: Faster than PHASTER, better than PHAST. Nucleic Acids Research, 51(W1), W443–W450.

Cited by: 394

4. Wishart, D. S., Tian, S., Allen, D., Oler, E., Peters, H., Lui, V. W., Gautam, V., … (2022). BioTransformer 3.0: A web server for accurately predicting metabolic transformation products. Nucleic Acids Research, 50(W1), W115–W123.

Cited by: 160

5. Wang, F., Allen, D., Tian, S., Oler, E., Gautam, V., Greiner, R., Metz, T. O., … (2022). CFM-ID 4.0: A web server for accurate MS-based metabolite identification. Nucleic Acids Research, 50(W1), W165–W174.

Cited by: 115

Dr. Vasuk Gautam’s work advances the reliability and scalability of metabolomic and biomarker research, enabling more accurate diagnostics and deeper biological insight. By developing robust identification metrics and contributing to global data resources, he helps accelerate scientific discovery, support precision medicine, and enhance evidence-based decision-making across research, healthcare, and industry.

Daniel Glossman-Mitnik | Computational Biology | Best Academic Researcher Award

Published on by Technology Scientists

Dr. Daniel Glossman-Mitnik | Computational Biology | Best Academic Researcher Award

Emeritus Researcher|Center for Research in Advanced Materials | Mexico

Dr. Daniel Glossman-Mitnik is a prominent researcher at the Centro de Investigación en Materiales Avanzados (CIMAV), Chihuahua, Mexico, recognized internationally for his extensive contributions to computational and theoretical chemistry. His work primarily employs Density Functional Theory (DFT) and Conceptual DFT (CDFT) to investigate the structural, electronic, and reactive properties of molecules and materials relevant to nanotechnology, materials science, and bioactive compounds. With a prolific record of 62 peer-reviewed publications, his research has accumulated over 817 citations, achieving an h-index of 19, which reflects the sustained impact and academic quality of his scientific output. Dr. Glossman-Mitnik’s recent studies encompass a wide spectrum of applications, including the design of triphenylamine-based sensitizers and Cu(I) complexes for dye-sensitized solar cells (DSSCs), as well as computational evaluations of marine natural products and therapeutic peptides for drug discovery. His scholarly endeavors are characterized by interdisciplinary collaboration, having co-authored with more than 120 researchers worldwide, fostering innovation through theoretical–experimental integration. Beyond his methodological expertise, his research has meaningful social and technological implications, contributing to advancements in renewable energy materials, environmentally sustainable chemical design, and computational approaches to pharmacology. By combining rigorous quantum-chemical modeling with practical applications, Dr. Glossman-Mitnik’s work exemplifies how theoretical insights can drive real-world scientific progress. His career reflects a profound commitment to advancing the global understanding of molecular behavior and material performance, positioning him as a leading figure in contemporary computational chemistry.

Profiles: Scopus | Google Scholar

Featured Publications

1. Rodríguez-Valdez, L. M., Villamisar, W., Casales, M., González-Rodríguez, J. G., & others. (2006). Computational simulations of the molecular structure and corrosion properties of amidoethyl, aminoethyl and hydroxyethyl imidazolines inhibitors. Corrosion Science, 48(12), 4053–4064.
Cited by: 248

2. Rodríguez-Valdez, L. M., Martínez-Villafañe, A., & Glossman-Mitnik, D. (2005). Computational simulation of the molecular structure and properties of heterocyclic organic compounds with possible corrosion inhibition properties. Journal of Molecular Structure: THEOCHEM, 713(1), 65–70.
Cited by: 233

3. Glossman-Mitnik, D. (2013). Computational study of the chemical reactivity properties of the Rhodamine B molecule. Procedia Computer Science, 18, 816–825.
Cited by: 131

4. Mendoza-Wilson, A. M., & Glossman-Mitnik, D. (2006). Theoretical study of the molecular properties and chemical reactivity of (+)-catechin and (−)-epicatechin related to their antioxidant ability. Journal of Molecular Structure: THEOCHEM, 761(1), 97–106.
Cited by: 130

5. Gallo, M., Favila, A., & Glossman-Mitnik, D. (2007). DFT studies of functionalized carbon nanotubes and fullerenes as nanovectors for drug delivery of antitubercular compounds. Chemical Physics Letters, 447(1), 105–109.
Cited by: 128

Dr. Daniel Glossman-Mitnik’s work advances global innovation by integrating computational chemistry with materials science and biomedicine, enabling the rational design of sustainable materials and therapeutic compounds. His research bridges theory and application, contributing to cleaner energy technologies, drug discovery, and the broader understanding of molecular behavior for societal and industrial benefit.